Phase 3, randomized trial (CheckMate 057) of nivolumab vs docetaxel in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): subgroup analyses and patient reported outcomes (PROs)

被引：0
作者：
Horn, L. [1 ]
Brahmer, J. [2 ]
Reck, M. [3 ]
Borghaei, H. [4 ]
Spigel, D. R. [5 ]
Steins, M. [6 ]
Ready, E. [7 ]
Chow, L. Q. [8 ]
Vokes, E. E. [9 ]
Felip, E. [10 ]
Holgado, E. [11 ]
Barlesi, F. [12 ]
Kohlhaeufl, M. [13 ]
Burgio, M. A. [14 ]
Fayette, J. [15 ]
Gettinger, S. N. [16 ]
Harbison, C. T. [17 ]
Li, A. [18 ]
Finckenstein, F. G. [19 ]
Paz-Ares, L. [20 ]
机构：
[1] Vanderbilt Ingram Canc Ctr, Dept Med, Nashville, TN USA
[2] Johns Hopkins Univ Hosp, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21287 USA
[3] LungenClin Grosshansdorf, Grosshansdorf, Germany
[4] Fox Chase Canc Ctr, Med Oncol, Philadelphia, PA 19111 USA
[5] Sarah Cannon Res Inst, Ctr Canc, Med Oncol, Nashville, TN USA
[6] Thoraxklin Heidelberg, Internal Med Oncol, Heidelberg, Germany
[7] Duke Univ, Med Ctr, Div Oncol, Durham, NC USA
[8] Univ Washington, Dept Med, Seattle Canc Care Alliance, Seattle, WA USA
[9] Univ Chicago, Med Ctr, Dept Med, Chicago, IL 60637 USA
[10] Vall dHebron Univ Hosp, Dept Oncol, Barcelona, Spain
[11] Hosp Madrid Norte, San Chinarro Ctr Integral Oncol Clara Campal, Serv Oncol, Madrid, Spain
[12] Hop Nord Marseille, Multidisciplinary Oncol & Therapeut Innovat, Marseille, France
[13] Klin Schillerhohe, Pneumonol & Pulm Oncol, Gerlingen, Germany
[14] Ist Sci Romagnolo Studio & Cura Tumori, Dept Med Oncol, Meldola, Italy
[15] Ctr Leon Berard, Oncol Med, F-69373 Lyon, France
[16] Yale Univ, Sch Med Med Oncol, Med Oncol, New Haven, CT USA
[17] Bristol Myers Squibb Co, ImmunoSci Metab Dis & Fibrosis, Princeton, NJ USA
[18] Bristol Myers Squibb Co, Oncol, Princeton, NJ USA
[19] Bristol Myers Squibb Co, Oncol Global Clin Res, Princeton, NJ USA
[20] Hosp Univ Virgen del Rocio, Serv Oncol Med, Seville, Spain
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
417O
引用
收藏
页码：125 / 125
页数：1
相关论文
共 50 条
  • [31] Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer
    Nishio, Makoto
    Hida, Toyoaki
    Atagi, Shinji
    Sakai, Hiroshi
    Nakagawa, Kazuhiko
    Takahashi, Toshiaki
    Nogami, Naoyuki
    Saka, Hideo
    Takenoyama, Mitsuhiro
    Maemondo, Makoto
    Ohe, Yuichiro
    Nokihara, Hiroshi
    Hirashima, Tomonori
    Tanaka, Hiroshi
    Fujita, Shiro
    Takeda, Koji
    Goto, Koichi
    Satouchi, Miyako
    Isobe, Hiroshi
    Minato, Koichi
    Sumiyoshi, Naoki
    Tamura, Tomohide
    ESMO OPEN, 2017, 2
  • [32] Economic Evaluation of Nivolumab Versus Docetaxel for the Treatment of Advanced Squamous and Non-squamous Non-small Cell Lung Cancer After Prior Chemotherapy in China
    Shanlian Hu
    Zhiliu Tang
    James P. Harrison
    Nadine Hertel
    John R. Penrod
    Jessica R. May
    Ariadna Juarez-Garcia
    Orban Holdgate
    PharmacoEconomics - Open, 2023, 7 : 273 - 284
  • [33] Economic Evaluation of Nivolumab Versus Docetaxel for the Treatment of Advanced Squamous and Non-squamous Non-small Cell Lung Cancer After Prior Chemotherapy in China
    Hu, Shanlian
    Tang, Zhiliu
    Harrison, James P.
    Hertel, Nadine
    Penrod, John R.
    May, Jessica R.
    Juarez-Garcia, Ariadna
    Holdgate, Orban
    PHARMACOECONOMICS-OPEN, 2023, 7 (02) : 273 - 284
  • [34] Maintenance chemotherapy in patients with non-squamous non-small cell lung cancer (NSCLC)
    Belalcazar, A.
    Santos, E. S.
    Gomez, J. E.
    Lopez, E.
    Raez, L. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [35] Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer (NSCLC): results of the phase 3 CheckMate 078 study
    Wu, Yi-Long
    Lu, Shun
    Cheng, Ying
    Zhou, Caicun
    Wang, Jie
    Mok, Tony
    Zhang, Li
    Tu, Haiyan
    Wu, Lin
    Feng, Jifeng
    Zhang, Yiping
    Luft, Alexander Valeriercich
    Zhou, Jianying
    Ma, Zhiyong
    Lu, You
    Hu, Chengping
    Shi, Yuankai
    Baudelet, Christine
    Li, Zoe
    Chang, Jianhua
    CANCER RESEARCH, 2018, 78 (13)
  • [36] KRAS molecular profiling in non-squamous non-small cell lung cancer (NSCLC).
    Karim, Nagla Abdel
    Starnes, Sandra
    Morris, John
    Pathrose, Peter
    Perry, Ashley
    Fathallah, Hassana
    CLINICAL CANCER RESEARCH, 2014, 20
  • [37] Dostarlimab plus chemotherapy (CT) vs pembrolizumab plus CT in metastatic non-squamous non-small cell lung cancer (NSCLC): Updated Asian subgroup analyses of the PERLA trial
    Lee, D. H.
    Ahn, J. S.
    Lin, S-H.
    Ulanska, M.
    Lopez, G. A.
    Chian, C-F.
    Cho, L.
    Szijgyarto, Z.
    Stjepanovic, N.
    Lim, S. M.
    ANNALS OF ONCOLOGY, 2023, 34 : S1662 - S1663
  • [38] PHASE II TRIAL OF BEVACIZUMAB PLUS DOCETAXEL IN PATIENTS WITH PREVIOUSLY TREATED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
    Ohyanagi, F.
    Kudo, K.
    Yanagitani, N.
    Horiike, A.
    Horai, T.
    Nishio, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 441 - 442
  • [39] Queensland state-wide patterns and access to EGFR mutation testing for metastatic, non-squamous non-small cell lung cancer (non-SQ NSCLC) from 2014 to 2021
    Niranjan, Navin
    Yang, Zane
    Mason, Robert
    Guan, Tracey
    Chan, Bryan A.
    Sanmugarajah, Jasotha
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2024, 20 : 145 - 146
  • [40] Impact of Social Economic Status on Patient Reported Outcomes (PROs) In Non-Small Cell Lung Cancer (NSCLC)
    Bachler, J.
    Wang, A.
    Poisson, L.
    Boakye, E. Adjei
    Tam, S.
    Gadgeel, S.
    Movsas, B.
    Potugari, B.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S716 - S716
12345